RG 4733

Drug Profile

RG 4733

Alternative Names: R 4733; RG4733; RO 4929097

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics; Benzazepines; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 19 Nov 2010 Suspended - Phase-II for Non-small cell lung cancer in Netherlands (PO)
  • 08 Jun 2010 Interim efficacy, pharmacodynamics, pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
  • 22 Apr 2009 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top